E-Therapeutics

Based on advances in chemical biology and network science, network pharmacology is a distinctive new approach to drug discovery. It involves application of network analysis to determine the set of proteins most critical in any disease, and then chemical biology to identify molecules capable of targeting that set of proteins. By addressing the true complexity of disease and by seeking to harness the ability of drugs to influence many different proteins, network pharmacology differs from conventional drug discovery approaches, which have generally been based on highly specific targeting of a single protein. Network pharmacology has the potential to provide new treatments for complex diseases where conventional approaches have failed to deliver satisfactory therapies.

Type
Public
HQ
Long Hanborough, GB
Founded
2003
Employees
27 (est)
E-Therapeutics was founded in 2003 and is headquartered in Long Hanborough, GB

Key People at E-Therapeutics

Malcolm Young

Malcolm Young

Chief Executive at e-Therapeutics plc
Sean Nicolson

Sean Nicolson

Executive Director
Stuart Lavin

Stuart Lavin

Clinical Operations Manager
Steve Self

Steve Self

Development Director / Consultant

E-Therapeutics Locations

Long Hanborough, GB

E-Therapeutics Metrics

E-Therapeutics Summary

Market capitalization

£22.5 M

Closing share price

£0.0838
E-Therapeutics's latest market capitalization is £22.5 M.

E-Therapeutics Market Value History

11% of current employees of E-Therapeutics are female and 89% are male.

E-Therapeutics News

E-Therapeutics Company Life

You may also be interested in